Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably - Preclinical Alzheimer's disease (BioFINDER Preclinical AD)
Following the previous BioFINDER-1 and BioFINDER-2 studies, the BioFINDER-Preclinical AD study was initiated to focus solely on the pre-symptomatic phase of Alzheimer’s disease (AD). The study screens a general population to recruit individuals with unimpaired cognition and elevated risk of dementia (i.e., APOE-e4 carrier, first degree family history of dementia or severe memory loss with onset prior to 75, or amyloid brain pathology). The study sample then recruits a 'Trial Ready' cohort with 600 participants with pre-symptomatic AD and an auxiliary control cohort with 200 matched controls without pre-symptomatic AD. The objective is to always have 600 participants in the Trial Ready Cohort, and all participants are followed up for four years.
Study design
Cohort
Number of participants at first data collection
800 (participants)
Recruitment is ongoing
Age at first data collection
50 - 80 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2022
Primary Institutions
Lund University (Lunds Universitet)
Skåne University Hospital (Skånes universitetssjukhus, SUS)
Profile paper DOI
Not available
Funders
No funding information available
Ongoing?
Yes
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – face-to-face
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- None
Engagement
Keywords
Consortia and dataset groups
